接受口服铁螯合剂（去铁酮）治疗的重型β地中海贫血患者的粒细胞缺乏症
Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone).
作者信息
Wali Yasser, Shidhani Azza Al, Daar Shahina
出版信息
Oman Med J. 2008 Oct;23(4):275-7.
Abstract
Deferiprone is an oral chelating agent that has been recently shown to reduce cardiac siderosis, but is also known to be associated with serious side effects like agranulocytosis which can be fatal. This report is a single centre experience of 5 cases with severe agranulocytosis in amongst 144 patients (3.47%) of thalassemia major on combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone which is much higher than the previous reports.
摘要
去铁酮是一种口服螯合剂，最近已显示其可减轻心脏铁沉积，但也已知其与严重副作用相关，如可能致命的粒细胞缺乏症。本报告是一项单中心经验，在144例接受皮下去铁胺和口服去铁酮联合螯合治疗的重型地中海贫血患者中，有5例发生严重粒细胞缺乏症（3.47%），这一比例远高于先前报告。
相似文献
1
2
Combined therapy with deferiprone and desferrioxamine in thalassemia major.去铁酮与去铁胺联合治疗重型地中海贫血
Haematologica. 2005 Oct;90(10):1309-14.
3
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.地拉罗司、去铁酮和去铁胺治疗地中海贫血症患者：通过定量磁共振成像评估心脏铁含量和功能的比较。
Haematologica. 2011 Jan;96(1):41-7. doi: 10.3324/haematol.2009.019042. Epub 2010 Sep 30.
4
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.地拉罗司治疗输血依赖型地中海贫血：综述与展望。
Ther Clin Risk Manag. 2007 Oct;3(5):795-805.
5
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.不同铁螯合剂对埃及铁过载β地中海贫血患儿的治疗效果。
Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721.
6
Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.去铁酮治疗输血依赖型地中海贫血患者的安全性和有效性。
Ther Adv Hematol. 2012 Oct;3(5):299-307. doi: 10.1177/2040620712450252.
7
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.去铁酮或去铁胺治疗重型β地中海贫血无症状心肌铁沉积患者的随机对照试验
Blood. 2006 May 1;107(9):3738-44. doi: 10.1182/blood-2005-07-2948. Epub 2005 Dec 13.
8
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.去铁胺与去铁酮联合治疗重型β地中海贫血输血性铁过载患者。
Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1.
9
Oral iron chelation with deferiprone.
Pediatr Clin North Am. 1997 Feb;44(1):235-47. doi: 10.1016/s0031-3955(05)70471-5.
10
Treatment of iron overload in thalassemia.地中海贫血中铁过载的治疗。
Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:208-13.
引用本文的文献
1
Prevalence and Molecular Evaluation of Hepatitis C Virus Infection among Multi-transfused Thalassemia Patients in South of Iran.伊朗南部多次输血的地中海贫血患者中丙型肝炎病毒感染的患病率及分子评估
Oman Med J. 2022 Sep 30;37(5):e427. doi: 10.5001/omj.2022.85. eCollection 2022 Sep.
2
The Effects of Medicago Sativa and Allium Porrum on Iron Overload in Rats.紫花苜蓿和韭葱对大鼠铁过载的影响。
Glob J Health Sci. 2015 Apr 23;7(7 Spec No):137-42. doi: 10.5539/gjhs.v7n7p137.
本文引用的文献
1
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.
Blood. 2007 Jun 15;109(12):5157-9. doi: 10.1182/blood-2007-02-065805. Epub 2007 Mar 7.
2
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.重型β地中海贫血患者从去铁胺治疗转换为去铁酮治疗后心肌功能障碍的消退
Hemoglobin. 2006;30(2):229-38. doi: 10.1080/03630260600642559.
3
4
Deferiprone: New insight.去铁酮：新见解。
Ann N Y Acad Sci. 2005;1054:169-74. doi: 10.1196/annals.1345.019.
5
Beta-thalassemia.β地中海贫血
N Engl J Med. 2005 Sep 15;353(11):1135-46. doi: 10.1056/NEJMra050436.
6
Deferiprone therapy for transfusional iron overload.去铁酮治疗输血性铁过载
Best Pract Res Clin Haematol. 2005 Jun;18(2):299-317. doi: 10.1016/j.beha.2004.08.026.
7
Safety of oral iron chelator deferiprone in young thalassaemics.
Eur J Haematol. 2005 Mar;74(3):217-20. doi: 10.1111/j.1600-0609.2004.00377.x.
8
New strategies in the treatment of the thalassemias.地中海贫血治疗的新策略。
Annu Rev Med. 2005;56:157-71. doi: 10.1146/annurev.med.56.082103.104718.
9
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
10
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.口服铁螯合剂去铁酮长期治疗的安全性和有效性。
Blood. 2003 Sep 1;102(5):1583-7. doi: 10.1182/blood-2002-10-3280. Epub 2003 May 22.
Zotero 插件